Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 11/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2427480 | 1.00 | EPHX2 (0.42) | EPHX2TRPM8TRPV1MGLL | |
| SCHEMBL2432969 | 0.90 | KMT2A (0.44) | EPHX2TRPM8TRPV1 | |
| SCHEMBL2427378 | 0.90 | KMT2A (0.44) | EPHX2TRPM8TRPV1 | |
| SCHEMBL2340825 | 0.89 | EPHX2 (0.44) | EPHX2TRPM8TRPV1 | |
| SCHEMBL12295624 | 0.89 | HTT (0.41) | EPHX2TRPM8 | |
| SCHEMBL2428277 | 0.86 | MGLL (0.51) | EPHX2TRPM8TRPV1MGLL | |
| SCHEMBL2427398 | 0.86 | MGLL (0.51) | EPHX2TRPM8TRPV1MGLL | |
| SCHEMBL2430997 | 0.86 | MGLL (0.51) | EPHX2TRPM8TRPV1MGLL | |
| SCHEMBL3347845 | 0.84 | MGLL (0.47) | EPHX2TRPM8TRPV1MGLL | |
| SCHEMBL3347840 | 0.84 | MGLL (0.47) | EPHX2TRPM8TRPV1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367830-A1 | 1-OXA-8-AZASPIRO [4, 5] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-09-28 | — | — | EP | claimed |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | claimed |
| WO-2010058318-A1 | 1-OXA-8-AZASPIRO [4, 5 ] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | PFIZER INC. (US) | 2010-05-27 | — | — | WO | claimed |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | FAAH, FAAH2, FFAR1 | EPHX2 670/4885TRPM8 1327/4885TRPV1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.